Skip to content
DataLookout
Menu

TICTOCNCT05156892

Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date changed from estimate of Jan 1, 2026 to Nov 1, 2026 Show 6 more changesShow less
    • Eligibility criteria expanded, about 33 words
    • Trial completed
    • Final enrollment: 12 participants (planned 44)
    • Secondary endpoints: details revised at 2 of 9 entries
    • Site details revised
    • Collaborators: details revised at 1 of 4 entries
  2. Notable Primary completion date: Jan 1, 2024 to Jan 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jan 1, 2025 to Jan 1, 2027
    • Site details revised
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 1, 2022 to Sep 4, 2022
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Recommended phase 2 dose of Tamoxifen in combination with Suba-itraconazole
Timeframe: 1 years

Secondary (7)

To determine overall response rate as determined by RECIST V1.1 and GCIG CA125 response criteria
To determine the duration of response
Incidence of Treatment-Emergent Adverse Events via CTCAE v5.0
Serum concentration of tamoxifen and derivatives
Tissue concentration of tamoxifen and derivatives
Show 2 moreShow less
Serum concentration of itraconazole
Tissue concentration of itraconazole

Arms and interventions

Dose-escalation/ expansionExperimental

SUBA-itraconazole (oral 150mg twice daily) and escalating dose of Tamoxifen (oral once daily) then expansion cohort

Drugs: SUBA-itraconazole, Tamoxifen

Sites

1 site in 1 country

  • Kinghorn Cancer Centre, St. Vincent's HospitalSydney, New South Wales, Australia